-
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-24 Joanna M Wardlaw, Lisa J Woodhouse, Iris I Mhlanga, Katherine Oatey, Anna K Heye, John Bamford, Vera Cvoro, Fergus N Doubal, Timothy England, Ahamad Hassan, Alan Montgomery, John T O'Brien, Christine Roffe, Nikola Sprigg, David J Werring, Philip M Bath
Cerebral small vessel disease (cSVD) is a common cause of stroke (lacunar stroke), is the most common cause of vascular cognitive impairment, and impairs mobility and mood but has no specific treatment.
-
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-22 Ruben Smith, Douglas Hägerström, Daria Pawlik, Gregory Klein, Jonas Jögi, Tomas Ohlsson, Erik Stomrud, Oskar Hansson
It is important to determine the added clinical value for tau positron emission tomography (PET) in the diagnostic workup of patients with cognitive symptoms before widespread implementation in clinical practice.
-
Segmental Uniparental Isodisomy Causing an "Inside-to-Outside" Limb-Girdle Muscular Dystrophy Due to a Homozygous Mutation in POGLUT1. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-22 Roula Ghaoui, Samuel Curtis, Karin S Kassahn
This case report describes segmental uniparental isodisomy causing an “inside-to-outside” limb-girdle muscular dystrophy due to a homozygous mutation in POGLUT1.
-
Safety and Efficacy of Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-22 Nadinda A M van der Ende, Bob Roozenbeek, Lucas E M Smagge, Sven P R Luijten, Leo A M Aerden, Petra Kraayeveld, Ido R van den Wijngaard, Geert J Lycklama À Nijeholt, Heleen M den Hertog, H Zwenneke Flach, Alida A Postma, Stefan D Roosendaal, G Menno Krietemeijer, Lonneke S F Yo, Moniek P M de Maat, Daan Nieboer, Gregory J Del Zoppo, William J Meurer, Hester F Lingsma, Aad van der Lugt, Diederik W J
Dual thrombolytic treatment with small bolus alteplase and mutant prourokinase has the potential to be a safer and more efficacious treatment for ischemic stroke than alteplase alone because mutant prourokinase is designed to act only on degraded fibrin without affecting circulating fibrinogen.
-
The Other Dementia Breakthrough-Comprehensive Dementia Care. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-22 David B Reuben, Gary Epstein-Lubow, Nora Super
This Viewpoint describes barriers to comprehensive dementia care and proposes strategies for overcoming them.
-
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-15 Samuel M Goldman, Frances M Weaver, Kevin T Stroupe, Lishan Cao, Beverly Gonzalez, Kalea Colletta, Ethan G Brown, Caroline M Tanner
An increased risk of Parkinson disease (PD) has been associated with exposure to the solvent trichloroethylene (TCE), but data are limited. Millions of people in the US and worldwide are exposed to TCE in air, food, and water.
-
Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-15 Michael Hittle, William J Culpepper, Annette Langer-Gould, Ruth Ann Marrie, Gary R Cutter, Wendy E Kaye, Laurie Wagner, Barbara Topol, Nicholas G LaRocca, Lorene M Nelson, Mitchell T Wallin
Racial, ethnic, and geographic differences in multiple sclerosis (MS) are important factors to assess when determining the disease burden and allocating health care resources.
-
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-08 Rachel F Buckley, Jessica Gong, Mark Woodward
This Viewpoint calls for comprehensive investigations into sex differences associated with treatments in existing Alzheimer disease and integration into future Alzheimer disease and related dementia clinical trials.
-
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-08 Antoine Leuzy, Alexa Pichet Binette, Jacob W Vogel, Gregory Klein, Edilio Borroni, Matteo Tonietto, Olof Strandberg, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Michael J Pontecorvo, Leonardo Iaccarino, Erik Stomrud, Rik Ossenkoppele, Ruben Smith, Oskar Hansson
Longitudinal tau positron emission tomography (PET) is a relevant outcome in clinical trials evaluating disease-modifying therapies in Alzheimer disease (AD). A key unanswered question is whether the use of participant-specific (individualized) regions of interest (ROIs) is superior to conventional approaches where the same ROI (group-level) is used for each participant.
-
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-08 Daniele Altomare, Frederik Barkhof, Camilla Caprioglio, Lyduine E Collij, Philip Scheltens, Isadora Lopes Alves, Femke Bouwman, Johannes Berkhof, Ingrid S van Maurik, Valentina Garibotto, Christian Moro, Julien Delrieu, Pierre Payoux, Laure Saint-Aubert, Anne Hitzel, José Luis Molinuevo, Oriol Grau-Rivera, Juan Domingo Gispert, Alexander Drzezga, Frank Jessen, Philip Zeyen, Agneta Nordberg, Irina Savitcheva
Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effect.
-
Computed Tomography Findings in Hyperacute Spontaneous Midbrain Hemorrhage. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-08 Juntao Yin, Wan Wang, Yuqing Wei
This case report describes the computed tomography (CT) characteristic findings and evolution of a hyperacute spontaneous midbrain hemorrhage.
-
Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-01 Sattar Khoshkhoo, Yilan Wang, Yasmine Chahine, E Zeynep Erson-Omay, Stephanie M Robert, Emre Kiziltug, Eyiyemisi C Damisah, Carol Nelson-Williams, Guangya Zhu, Wenna Kong, August Yue Huang, Edward Stronge, H Westley Phillips, Brian H Chhouk, Sara Bizzotto, Ming Hui Chen, Thiuni N Adikari, Zimeng Ye, Tom Witkowski, Dulcie Lai, Nadine Lee, Julie Lokan, Ingrid E Scheffer, Samuel F Berkovic, Shozeb Haider
Mesial temporal lobe epilepsy (MTLE) is the most common focal epilepsy subtype and is often refractory to antiseizure medications. While most patients with MTLE do not have pathogenic germline genetic variants, the contribution of postzygotic (ie, somatic) variants in the brain is unknown.
-
Rheumatoid Arthritis and Risk of Parkinson Disease in Korea. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-01 Jihun Kang, Yeonghee Eun, Wooyoung Jang, Mi Hee Cho, Kyungdo Han, Jinhyoung Jung, Yunkyung Kim, Gun-Tae Kim, Dong Wook Shin, Hyungjin Kim
Although it has been postulated that chronic inflammation caused by rheumatoid arthritis (RA) contributes to the development of Parkinson disease (PD), the association between these 2 conditions has yet to be determined.
-
The Cynicism of the Seronegative. JAMA Neurol. (IF 29.907) Pub Date : 2023-05-01 Mark F Carroll
A physician in his 70s describes his path to a diagnosis of inflammatory arthritis, which included completely normal laboratory results.
-
Advocating for Demonstration of Disease Modification-Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly? JAMA Neurol. (IF 29.907) Pub Date : 2023-04-24 Vincent Planche, Nicolas Villain
This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.
-
Ultrasonography of Muscle Vibration Caused by MYBPC1 Variant. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-24 Ying Zhao, Chuanzhu Yan, Kunqian Ji
This case report describes muscle vibration during muscle contraction caused by an MYBPC1 variant.
-
Characteristics of Progressive Multifocal Leukoencephalopathy Associated With Sarcoidosis Without Therapeutic Immune Suppression. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-24 Caleb R S McEntire, Anita Fletcher, Michel Toledano, Samantha Epstein, Emily White, C Sabrina Tan, Yang Mao-Draayer, Samantha A Banks, Allen J Aksamit, Jeffrey M Gelfand, Kiran T Thakur, Pria Anand, Irene Cortese, Shamik Bhattacharyya
Progressive multifocal leukoencephalopathy can occur in the context of systemic sarcoidosis (S-PML) in the absence of therapeutic immune suppression and can initially be mistaken for neurosarcoidosis or other complications of sarcoidosis. Earlier recognition of S-PML could lead to more effective treatment of the disease.
-
Trends in the Prevalence of Stroke Among Community-Dwelling Individuals in the US, 1999-2018. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-24 Wells Andres, Aaron Rothstein, Holly Elser, Kelly L Sloane, Rebecca F Gottesman, Scott E Kasner, Andrea L C Schneider
This cross-sectional study estimates trends in stroke prevalence representative of the noninstitutionalized civilian population of US adults 20 years and older using data from the 1999 to 2018 National Health and Nutrition Examination Surveys.
-
Lentiform Fork Sign on Magnetic Resonance Imaging After Methamphetamine and Alcohol Misuse. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-17 Juliane Hiesgen, Jacques Badenhorst
This case report describes a patient with a 3-day history of acute blindness after using alcohol and methamphetamine for 3 consecutive nights before onset of visual impairment.
-
Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-17 Julie Werenberg Dreier, Marte-Helene Bjørk, Silje Alvestad, Mika Gissler, Jannicke Igland, Maarit K Leinonen, Yuelian Sun, Helga Zoega, Jacqueline M Cohen, Kari Furu, Torbjörn Tomson, Jakob Christensen
Prenatal antiseizure medication (ASM) exposure has been associated with adverse early neurodevelopment, but associations with a wider range of psychiatric end points have not been studied.
-
Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-17 Chris Moran, Mary E Lacy, Rachel A Whitmer, Ai-Lin Tsai, Charles P Quesenberry, Andrew J Karter, Alyce S Adams, Paola Gilsanz
The levels of glycemic control associated with the lowest risk of dementia in people with type 2 diabetes are unknown. This knowledge is critical to inform patient-centered glycemic target setting.
-
Incorporating the Central Vein Sign Into the Diagnostic Criteria for Multiple Sclerosis. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-17 Daniel Ontaneda, Jeffrey A Cohen, Pascal Sati
This Viewpoint discusses incorporating the central vein sign into the diagnostic criteria for multiple sclerosis.
-
Association of Mortality and Risk of Epilepsy With Type of Acute Symptomatic Seizure After Ischemic Stroke and an Updated Prognostic Model. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-10 Lucia Sinka, Laura Abraira, Lukas L Imbach, Dominik Zieglgänsberger, Estevo Santamarina, José Álvarez-Sabín, Carolina Ferreira-Atuesta, Mira Katan, Natalie Scherrer, Giulio Bicciato, Robert Terziev, Cyril Simmen, Kai Michael Schubert, Adham Elshahabi, Christian R Baumann, Nico Döhler, Barbara Erdélyi-Canavese, Ansgar Felbecker, Philip Siebel, Michael Winklehner, Tim J von Oertzen, Judith N Wagner,
Acute symptomatic seizures occurring within 7 days after ischemic stroke may be associated with an increased mortality and risk of epilepsy. It is unknown whether the type of acute symptomatic seizure influences this risk.
-
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-10 Priya S Kishnani, Jordi Diaz-Manera, Antonio Toscano, Paula R Clemens, Shafeeq Ladha, Kenneth I Berger, Hani Kushlaf, Volker Straub, Gerson Carvalho, Tahseen Mozaffar, Mark Roberts, Shahram Attarian, Yin-Hsiu Chien, Young-Chul Choi, John W Day, Sevim Erdem-Ozdamar, Sergey Illarioshkin, Ozlem Goker-Alpan, Anna Kostera-Pruszczyk, Ans T van der Ploeg, Kristina An Haack, Olivier Huynh-Ba, Swathi Tammireddy
In the previously reported Comparative Enzyme Replacement Trial With neoGAA Versus rhGAA (COMET) trial, avalglucosidase alfa treatment for 49 weeks showed clinically meaningful improvements in upright forced vital capacity (FVC) percent predicted and 6-minute walk test (6MWT) compared with alglucosidase alfa.
-
Severe Hippocampal Atrophy in a Patient With Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-10 Frederik Bartels, Josephine Heine, Carsten Finke
This case report describes a patient who presented with headache, fever, quadriparesis, and reduced visual acuity in the left eye and 6 months later presented with persistent quadriparesis and new-onset cognitive deficits.
-
An Integrated Interdisciplinary Sleep Care Model-The Ultimate Dream Team. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-10 Sara E Benjamin, Elliott N Exar, Charlene E Gamaldo
This Viewpoint discusses the need for diverse physicians to manage sleep health.
-
Focal Cortex Stimulation With a Novel Implantable Device and Antiseizure Outcomes in 2 Prospective Multicenter Single-Arm Trials. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-03 Andreas Schulze-Bonhage, Martin Hirsch, Susanne Knake, Elisabeth Kaufmann, Josua Kegele, Michael Rademacher, Kristl Vonck, Volker Arnd Coenen, Martin Glaser, Carolin Jenkner, Yaroslav Winter, Sergiu Groppa
For the large population of people with drug-refractory epilepsy, alternative treatment approaches are needed. Clinical trial outcomes of a novel stimulation device, which is newly available in Europe for the treatment of patients with a predominant seizure focus, are reported for the first time.
-
Outcomes After Endovascular Therapy With Procedural Sedation vs General Anesthesia in Patients With Acute Ischemic Stroke: The AMETIS Randomized Clinical Trial. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-03 Russell Chabanne, Thomas Geeraerts, Marc Begard, Baptiste Balança, Francesca Rapido, Vincent Degos, Benoit Tavernier, Serge Molliex, Lionel Velly, Franck Verdonk, Anne-Claire Lukaszewicz, Pierre-François Perrigault, Jean-François Albucher, Christophe Cognard, Adrien Guyot, Charlotte Fernandez, Aurélie Masgrau, Ricardo Moreno, Anna Ferrier, Samir Jaber, Jean-Etienne Bazin, Bruno Pereira, Emmanuel Futier
General anesthesia and procedural sedation are common practice for mechanical thrombectomy in acute ischemic stroke. However, risks and benefits of each strategy are unclear.
-
Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission Tomography. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-03 Gillian T Coughlan, Tobey J Betthauser, Rory Boyle, Rebecca L Koscik, Hannah M Klinger, Lori B Chibnik, Erin M Jonaitis, Wai-Ying Wendy Yau, Allen Wenzel, Bradley T Christian, Carey E Gleason, Ursula G Saelzler, Michael J Properzi, Aaron P Schultz, Bernard J Hanseeuw, JoAnn E Manson, Dorene M Rentz, Keith A Johnson, Reisa Sperling, Sterling C Johnson, Rachel F Buckley
Postmenopausal females represent around 70% of all individuals with Alzheimer disease. Previous literature shows elevated levels of tau in cognitively unimpaired postmenopausal females compared with age-matched males, particularly in the setting of high β-amyloid (Aβ). The biological mechanisms associated with higher tau deposition in female individuals remain elusive.
-
Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-03 Lawren VandeVrede, Renaud La Joie, Elisabeth H Thijssen, Breton M Asken, Stephanie A Vento, Torie Tsuei, Suzanne L Baker, Yann Cobigo, Corrina Fonseca, Hilary W Heuer, Joel H Kramer, Peter A Ljubenkov, Gil D Rabinovici, Julio C Rojas, Howie J Rosen, Adam M Staffaroni, Brad F Boeve, Brad C Dickerson, Murray Grossman, Edward D Huey, David J Irwin, Irene Litvan, Alexander Y Pantelyat, Maria Carmela Tartaglia
Plasma phosphorylated tau217 (p-tau217), a biomarker of Alzheimer disease (AD), is of special interest in corticobasal syndrome (CBS) because autopsy studies have revealed AD is the driving neuropathology in up to 40% of cases. This differentiates CBS from other 4-repeat tauopathy (4RT)-associated syndromes, such as progressive supranuclear palsy Richardson syndrome (PSP-RS) and nonfluent primary progressive
-
Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain. JAMA Neurol. (IF 29.907) Pub Date : 2023-04-03 Ahmed Abdelhak, Jens Kuhle, Ari J Green
This Viewpoint describes the benefits and limitations of using neurofilament light chain (NfL) as a marker of real-time disease activity and treatment response in multiple sclerosis.
-
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-29 Shorena Janelidze, Nicolas R Barthélemy, Yingxin He, Randall J Bateman, Oskar Hansson
Chronic kidney disease (CKD) has been associated with increased plasma concentrations of phosphorylated tau (p-tau) 217 and p-tau181, which potentially decreases their usefulness in the diagnostic workup of Alzheimer disease (AD).
-
Hello, My Name is Doctor. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-27 Eleanor R Menzin
This essay describes a physician’s opinion of why using only a first name can be confusing rather than aiding in resolving inequalities between physicians and other hospital staff or patients.
-
Association of Dementia Risk With Focal Epilepsy and Modifiable Cardiovascular Risk Factors. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-27 Xin You Tai, Emma Torzillo, Donald M Lyall, Sanjay Manohar, Masud Husain, Arjune Sen
Epilepsy has been associated with cognitive impairment and potentially dementia in older individuals. However, the extent to which epilepsy may increase dementia risk, how this compares with other neurological conditions, and how modifiable cardiovascular risk factors may affect this risk remain unclear.
-
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-20 Patric Liang, Jack L Cronenwett, Eric A Secemsky, Jens Eldrup-Jorgensen, Mahmoud B Malas, Grace J Wang, Brian W Nolan, Vikram S Kashyap, Raghu L Motaganahalli, Marc L Schermerhorn
Carotid artery stenting has been limited to use in patients with high surgical risk; outcomes in patients with standard surgical risk are not well known.
-
Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention: A Meta-analysis and Meta-Regression. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-20 Chia-Yu Hsu, Jeffrey L Saver, Bruce Ovbiagele, Yi-Ling Wu, Chun-Yu Cheng, Meng Lee
The degree to which more intensive blood pressure reduction is better than less intensive for secondary stroke prevention has not been delineated.
-
Quantification of Penumbral Volume in Association With Time From Stroke Onset in Acute Ischemic Stroke With Large Vessel Occlusion. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-20 Pierre Seners, Nicole Yuen, Michael Mlynash, Sarah J Snyder, Jeremy J Heit, Maarten G Lansberg, Soren Christensen, Jean-François Albucher, Christophe Cognard, Igor Sibon, Michael Obadia, Julien Savatovsky, Jean-Claude Baron, Jean-Marc Olivot, Gregory W Albers
The benefit of reperfusion therapies for acute ischemic stroke decreases over time. This decreasing benefit is presumably due to the disappearance of salvageable ischemic brain tissue (ie, the penumbra).
-
Comparison of Perinatal Outcomes for Women With and Without Epilepsy: A Systematic Review and Meta-analysis. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-13 Paolo Pierino Mazzone, Kirsty Mhairi Hogg, Christopher J Weir, Jacqueline Stephen, Sohinee Bhattacharya, Richard F M Chin
Pregnant women who have epilepsy need adequate engagement, information, and pregnancy planning and management to improve pregnancy outcomes.
-
Multimodal Neuroimaging of Intimal Flap in a Basilar Artery Dissection. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-13 Marialuisa Zedde, Claudio Moratti, Rosario Pascarella
This case report describes a spontaneous dissection of the basilar artery in a 53-year-old man presenting with ischemic stroke.
-
A Step Forward in the Fight Against Dementia-Are We There Yet? JAMA Neurol. (IF 29.907) Pub Date : 2023-03-13 David A Wolk, Gil D Rabinovici, Bradford C Dickerson
This Viewpoint reports on the results of the Clarity AD trial, a phase 3 randomized clinical trial of lecanemab for patients with early Alzheimer disease, in which lecanemab’s clinical efficacy was demonstrated using well-established outcome measures.
-
Lecanemab and APOE Genotyping in Clinical Practice-Navigating Uncharted Terrain. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-13 Madhav Thambisetty, Robert Howard
This Viewpoint discusses the findings of the Clarity AD trial, which studied lecanemab for patients with early-stage Alzheimer disease.
-
Physical Frailty, Genetic Predisposition, and Incident Parkinson Disease. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-13 Zekun Zheng, Yanling Lv, Shuang Rong, Taoping Sun, Liangkai Chen
Cross-sectional evidence implicates high prevalent frailty in patients with Parkinson disease (PD), whereas the longitudinal association remains unknown.
-
Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-06 Nicholas J Ashton, Marion Moseby-Knappe, Andrea L Benedet, Lana Grötschel, Juan Lantero-Rodriguez, Thomas K Karikari, Christian Hassager, Matt P Wise, Pascal Stammet, Jesper Kjaergaard, Hans Friberg, Niklas Nielsen, Tobias Cronberg, Henrik Zetterberg, Kaj Blennow
Blood phosphorylated tau (p-tau) and amyloid-β peptides (Aβ) are promising peripheral biomarkers of Alzheimer disease (AD) pathology. However, their potential alterations due to alternative mechanisms, such as hypoxia in patients resuscitated from cardiac arrest, are not known.
-
Limb to Cranial Overflow Dystonia in a Patient After Stroke. JAMA Neurol. (IF 29.907) Pub Date : 2023-03-06 Arka Prava Chakraborty, Adreesh Mukherjee, Atanu Biswas
This case report describes noncontiguous overflow dystonia in a patient with diabetes, hypertension, and a history of left putaminal hemorrhage and right hemiparesis.
-
Modern Neurology Training Is Failing Outpatients. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-27 Louise M Klebanoff, Joseph E Safdieh
This Viewpoint describes the pressure on neurology residents to pursue subspecialty training in a fellowship program even though the need for general neurologists is sizable and increasing.
-
Prevalence, Timing, and Network Localization of Emergent Visual Creativity in Frontotemporal Dementia. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-27 Adit Friedberg, Lorenzo Pasquini, Ryan Diggs, Erika A Glaubitz, Lucia Lopez, Ignacio Illán-Gala, Leonardo Iaccarino, Renaud La Joie, Nidhi Mundada, Marguerite Knudtson, Kyra Neylan, Jesse Brown, Isabel Elaine Allen, Katherine P Rankin, Luke W Bonham, Jennifer S Yokoyama, Eliana M Ramos, Daniel H Geschwind, Salvatore Spina, Lea T Grinberg, Zachary A Miller, Joel H Kramer, Howard Rosen, Maria Luisa Gorno-Tempini
The neurological substrates of visual artistic creativity (VAC) are unknown. VAC is demonstrated here to occur early in frontotemporal dementia (FTD), and multimodal neuroimaging is used to generate a novel mechanistic hypothesis involving dorsomedial occipital cortex enhancement. These findings may illuminate a novel mechanism underlying human visual creativity.
-
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-27 Enric Monreal, José Ignacio Fernández-Velasco, María Isabel García-Sánchez, Susana Sainz de la Maza, Sara Llufriu, Roberto Álvarez-Lafuente, Bonaventura Casanova, Manuel Comabella, Lluís Ramió-Torrentà, José Enrique Martínez-Rodríguez, Luis Brieva, Albert Saiz, Sara Eichau, José María Cabrera-Maqueda, Noelia Villarrubia, Mercedes Espiño, Francisco Pérez-Miralles, Xavier Montalbán, Mar Tintoré, Ana
The value of serum neurofilament light chain (sNfL) levels for predicting long-term disability in patients with multiple sclerosis (MS) remains controversial.
-
Optimal Intensity and Duration of Walking Rehabilitation in Patients With Chronic Stroke: A Randomized Clinical Trial. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-23 Pierce Boyne, Sandra A Billinger, Darcy S Reisman, Oluwole O Awosika, Sofia Buckley, Jamiah Burson, Daniel Carl, Matthew DeLange, Sarah Doren, Melinda Earnest, Myron Gerson, Madison Henry, Alli Horning, Jane C Khoury, Brett M Kissela, Abigail Laughlin, Kiersten McCartney, Thomas McQuaid, Allison Miller, Alexandra Moores, Jacqueline A Palmer, Heidi Sucharew, Elizabeth D Thompson, Erin Wagner, Jaimie
For walking rehabilitation after stroke, training intensity and duration are critical dosing parameters that lack optimization.
-
Trends in Postmortem Neurodegenerative and Cerebrovascular Neuropathologies Over 25 Years. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-20 Francine Grodstein, Sue E Leurgans, Ana W Capuano, Julie A Schneider, David A Bennett
With rapid aging of the US population, understanding trends over time in dementia occurrence is essential to public health planning and intervention; this understanding includes trends in neuropathologies underlying clinical dementia.
-
Bibrachial Amyotrophy Due to Spontaneous Spinal Cerebrospinal Fluid Leak. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-20 Wouter I Schievink, Marcel M Maya
This case report describes a patient with bibrachial amyotrophy due to spontaneous spinal cerebrospinal fluid leak.
-
State-Level Indicators of Childhood Educational Quality and Incident Dementia in Older Black and White Adults. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-13 Yenee Soh, Rachel A Whitmer, Elizabeth Rose Mayeda, M Maria Glymour, Rachel L Peterson, Chloe W Eng, Charles P Quesenberry, Jennifer J Manly, Paola Gilsanz
Higher educational attainment is associated with reduced dementia risk, but the role of educational quality is understudied, presenting a major evidence gap, especially as it may contribute to racial inequities.
-
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-13 Sarah Dybowski, Sebastian Torke, Martin S Weber
Currently, disease-modifying therapies for multiple sclerosis (MS) use 4 mechanisms of action: immune modulation, suppressing immune cell proliferation, inhibiting immune cell migration, or cellular depletion. Over the last decades, the repertoire substantially increased because of the conceptual progress that not only T cells but also B cells play an important pathogenic role in MS, fostered by the
-
Views From Both Sides of the White Coat. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-13 Scott Eveloff
This essay describes the author’s experience as a physician-parent of a chronically ill child.
-
Changes in the Rate of Leucine-Rich Glioma-Inactivated 1 Seropositivity During the COVID-19 Lockdown. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-13 Adam E Handel, Jacqueline Palace, Elizabeth Bateman, Patrick Waters, Sarosh R Irani
This case-control study investigates the positivity rates of the most prevalent neuroglial surface antibodies during the COVID-19 pandemic.
-
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-06 Niklas Mattsson-Carlgren, Gemma Salvadó, Nicholas J Ashton, Pontus Tideman, Erik Stomrud, Henrik Zetterberg, Rik Ossenkoppele, Tobey J Betthauser, Karly Alex Cody, Erin M Jonaitis, Rebecca Langhough, Sebastian Palmqvist, Kaj Blennow, Shorena Janelidze, Sterling C Johnson, Oskar Hansson
Alzheimer disease (AD) pathology starts with a prolonged phase of β-amyloid (Aβ) accumulation without symptoms. The duration of this phase differs greatly among individuals. While this disease phase has high relevance for clinical trial designs, it is currently unclear how to best predict the onset of clinical progression.
-
It's Time to Rebrand "Mommy Brain". JAMA Neurol. (IF 29.907) Pub Date : 2023-02-06 Clare McCormack, Bridget L Callaghan, Jodi L Pawluski
This Viewpoint discusses the concept of “mommy brain” and why it needs to change.
-
Magnetic Resonance Imaging Features of GABA-A Receptor Antibody-Mediated Encephalitis. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-06 Omar Baqal, Aimen Vanood, Ehab Harahsheh
This case report describes a patient with status epilepticus and neuroimaging features of fleeting T2 fluid-attenuated inversion recovery hyperintense lesions on magnetic resonance imaging.
-
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurol. (IF 29.907) Pub Date : 2023-02-06 Stephanie Meier, Eline A J Willemse, Sabine Schaedelin, Johanna Oechtering, Johannes Lorscheider, Lester Melie-Garcia, Alessandro Cagol, Muhamed Barakovic, Riccardo Galbusera, Suvitha Subramaniam, Christian Barro, Ahmed Abdelhak, Simon Thebault, Lutz Achtnichts, Patrice Lalive, Stefanie Müller, Caroline Pot, Anke Salmen, Giulio Disanto, Chiara Zecca, Marcus D'Souza, Annette Orleth, Michael Khalil,
There is a lack of validated biomarkers for disability progression independent of relapse activity (PIRA) in multiple sclerosis (MS).
-
Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial. JAMA Neurol. (IF 29.907) Pub Date : 2023-01-30 Jacqueline J Bosch, Martin J O'Donnell, Peggy Gao, Philip Joseph, Prem Pais, Denis Xavier, Antonio Dans, Patricio Lopez Jaramillo, Salim Yusuf
Vascular risk factors are associated with cognitive decline but studies addressing individual risk factors have not demonstrated an effect of risk factor management on the preservation of cognition. Few trials have examined the effect of vascular risk factor management on function.
-
Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries. JAMA Neurol. (IF 29.907) Pub Date : 2023-01-30 Giancarlo Logroscino, Marco Piccininni, Caroline Graff, Orla Hardiman, Albert C Ludolph, Fermin Moreno, Markus Otto, Anne M Remes, James B Rowe, Harro Seelaar, Eino Solje, Elka Stefanova, Latchezar Traykov, Vesna Jelic, Melissa Taheri Rydell, Niall Pender, Sarah Anderl-Straub, Myriam Barandiaran, Alazne Gabilondo, Johanna Krüger, Alexander G Murley, Timothy Rittman, Emma L van der Ende, John C van
Diagnostic incidence data for syndromes associated with frontotemporal lobar degeneration (FTLD) in multinational studies are urgent in light of upcoming therapeutic approaches.